In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ... Clarivate's drugs to watch in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback